Acorah Software Products - Accounts Production 19.3.550 false true true 30 November 2024 1 December 2023 false 1 December 2024 30 November 2025 30 November 2025 13773831 Dr Adam Amara Dr Remy Jean Adrien Boutonnet Mr James Oliver Macfarlane iso4217:GBP iso4217:EUR iso4217:USD xbrli:shares xbrli:pure xbrli:pure 13773831 2024-11-30 13773831 2025-11-30 13773831 2024-12-01 2025-11-30 13773831 frs-core:CurrentFinancialInstruments 2025-11-30 13773831 frs-core:ComputerEquipment 2025-11-30 13773831 frs-core:ComputerEquipment 2024-12-01 2025-11-30 13773831 frs-core:ComputerEquipment 2024-11-30 13773831 frs-core:SharePremium 2025-11-30 13773831 frs-core:ShareCapital 2025-11-30 13773831 frs-core:RetainedEarningsAccumulatedLosses 2025-11-30 13773831 frs-bus:PrivateLimitedCompanyLtd 2024-12-01 2025-11-30 13773831 frs-bus:FilletedAccounts 2024-12-01 2025-11-30 13773831 frs-bus:SmallEntities 2024-12-01 2025-11-30 13773831 frs-bus:AuditExempt-NoAccountantsReport 2024-12-01 2025-11-30 13773831 frs-bus:SmallCompaniesRegimeForAccounts 2024-12-01 2025-11-30 13773831 frs-bus:OrdinaryShareClass1 2024-12-01 2025-11-30 13773831 frs-bus:OrdinaryShareClass1 2025-11-30 13773831 frs-bus:OrdinaryShareClass2 2024-12-01 2025-11-30 13773831 frs-bus:OrdinaryShareClass2 2025-11-30 13773831 frs-core:CostValuation 2024-11-30 13773831 frs-core:CostValuation 2025-11-30 13773831 frs-core:ProvisionsForImpairmentInvestments 2024-11-30 13773831 frs-core:ProvisionsForImpairmentInvestments 2025-11-30 13773831 frs-bus:Director1 2024-12-01 2025-11-30 13773831 frs-bus:Director2 2024-12-01 2025-11-30 13773831 frs-bus:Director3 2024-12-01 2025-11-30 13773831 frs-countries:EnglandWales 2024-12-01 2025-11-30 13773831 frs-core:Subsidiary1 2024-12-01 2025-11-30 13773831 frs-core:Subsidiary1 1 2024-12-01 2025-11-30 13773831 2023-11-30 13773831 2024-11-30 13773831 2023-12-01 2024-11-30 13773831 frs-core:CurrentFinancialInstruments 2024-11-30 13773831 frs-core:SharePremium 2024-11-30 13773831 frs-core:ShareCapital 2024-11-30 13773831 frs-core:RetainedEarningsAccumulatedLosses 2024-11-30 13773831 frs-bus:OrdinaryShareClass1 2023-12-01 2024-11-30 13773831 frs-bus:OrdinaryShareClass2 2023-12-01 2024-11-30
Registered number: 13773831
Turing Biosystems Ltd
Unaudited Financial Statements
For The Year Ended 30 November 2025
Wilson Partners Ltd
Ketton Suite The King Centre, Main Road
Barleythorpe
Oakham
LE15 7WD
Turing Biosystems Ltd
Contents
Contents

| Page
--- | ---
Balance Sheet | 1—2
Notes to the Financial Statements | 3—6

Page 1
Turing Biosystems Ltd
Balance Sheet
As At 30 November 2025
Balance Sheet
Registered number: 13773831

| 2025 | 2024
--- | --- | ---
| Notes | £ | £ | £ | £
FIXED ASSETS
Tangible Assets | 4 |  | 1,477 |  | 1,058
Investments | 5 |  | 84 |  | 84
|  |  | 1,561 |  | 1,142
CURRENT ASSETS
Debtors | 6 | 122,998 |  | 113,596 |
Cash at bank and in hand |  | 681,421 |  | 1,235,679 |
|  | 804,419 |  | 1,349,275 |
Creditors: Amounts Falling Due Within One Year | 7 | (11,836 ) |  | (31,706 ) |
NET CURRENT ASSETS (LIABILITIES) |  |  | 792,583 |  | 1,317,569
TOTAL ASSETS LESS CURRENT LIABILITIES |  |  | 794,144 |  | 1,318,711
NET ASSETS |  |  | 794,144 |  | 1,318,711
CAPITAL AND RESERVES
Called up share capital | 8 |  | 1,469 |  | 1,469
Share premium account |  |  | 1,974,948 |  | 1,974,948
Profit and Loss Account |  |  | (1,182,273 ) |  | (657,706 )
SHAREHOLDERS' FUNDS |  |  | 794,144 |  | 1,318,711

Page 1
Page 2
Turing Biosystems Ltd
Balance Sheet (continued)
As At 30 November 2025
For the year ending 30 November 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.
On behalf of the board

Dr Remy Jean Adrien Boutonnet Director
23 July 2026

The notes on pages 3 to 6 form part of these financial statements.
Page 2
Page 3
Turing Biosystems Ltd
Notes to the Financial Statements
For The Year Ended 30 November 2025
Notes to the Financial Statements
1. General Information
Turing Biosystems Ltd is a private company, limited by shares, incorporated in England & Wales, registered number 13773831 . The registered office is 37 Cremer Street, Workspace Brickfields, Office 303, London, E2 8HD.
2. Accounting Policies
2.1. Basis of Preparation of Financial Statements
The financial statements have been prepared under the historical cost convention and in accordance with Financial Reporting Standard 102 section 1A Small Entities "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.
The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.
2.2. Going Concern Disclosure
The directors have not identified any material uncertainties related to events or conditions that may cast significant doubt about the company's ability to continue as a going concern. Therefore the financial statements have been prepared on a going concern basis which assumes the Company will continue in operational existence for the foreseeable future.
The Company is involved in research and development activities and is working towards achieving a sustainable revenue generating activity. The directors have considered the basis of the financial statements and are satisfied that a combination of business growth and further investment commitments will enable the Company to meet its liabilities as they fall due.
2.3. Tangible Fixed Assets and Depreciation
Tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. Depreciation is provided at rates calculated to write off the cost of the fixed assets, less their estimated residual value, over their expected useful lives on the following bases:

Computer Equipment | 3 years, straight line

2.4. Investments
Investments in subsidiaries, associates and joint ventures are measured at cost less any accumulated impairment losses. Listed investments are measured at fair value where the difference between cost and fair value is material. Unlisted investments are measured at fair value unless the value cannot be measured reliably, in which case they are measured at cost less any accumulated impairment losses. Changes in fair value are included in the profit and loss account.
2.5. Cash and Cash Equivalents
Cash and cash equivalents are basic financial assets and include cash in hand and deposits held at call with banks, other short-term highly liquid investments that mature in no more than three months from the date of acquisition and are readily convertible to a known amount of cash with insignificant risk of change in value, and bank overdrafts.
2.6. Financial Instruments
The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.
Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.
Basic financial assets
Basic financial assets, which include debtors and bank balances, are measured at transaction price including transaction costs.
Classification of financial liabilities
Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.
Basic financial liabilities
Basic financial liabilities, including creditors, are recognised at transaction price including transaction costs.
Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities.
Page 3
Page 4
Turing Biosystems Ltd
Notes to the Financial Statements (continued)
For The Year Ended 30 November 2025
2.7. Foreign Currencies
Monetary assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate ruling on the date of the transaction. Exchange differences are taken into account in arriving at the profit / loss before taxation.
2.8. Taxation
Tax is recognised in profit or loss except that a charge is attributable to an item of income and expense recognised as other comphrehensive income or to an item recognised directly in equity is also recognised in other comphrehensive income or directly in equity respectively.
The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the company operates and generates income.
2.9. Pensions
The company operates a defined pension contribution scheme. Contributions are charged to the profit and loss account as they become payable in accordance with the rules of the scheme.
2.10. Research and Development
In the research phase of an internal project, it is not possible to demonstrate that the project will generate future economic benefits and hence all expenditure on research shall be recognised as an expense when it is incurred. Intangible assets are recognised from the development phase of a project if and only if certain specific criteria are met in order to demonstrate the asset will generate probable future economic benefits and that its cost can be reliably measured. The capitalised development costs are subsequently amortised on a straight-line basis over their useful economic lives.
If it is not possible to distinguish between the research phase and the development phase of an internal project, the expenditure is treated as if it were all incurred in the research phase only.
3. Average Number of Employees
Average number of employees, including directors, during the year was: 3 (2024: 1)
3 1
4. Tangible Assets

| Computer Equipment
--- | ---
| £
Cost
As at 1 December 2024 | 2,282
Additions | 1,481
As at 30 November 2025 | 3,763
Depreciation
As at 1 December 2024 | 1,224
Provided during the period | 1,062
As at 30 November 2025 | 2,286
Net Book Value
As at 30 November 2025 | 1,477
As at 1 December 2024 | 1,058

Page 4
Page 5
Turing Biosystems Ltd
Notes to the Financial Statements (continued)
For The Year Ended 30 November 2025
5. Investments

| Subsidiaries
--- | ---
| £
Cost or Valuation
As at 1 December 2024 | 84
As at 30 November 2025 | 84
Provision
As at 1 December 2024 | -
As at 30 November 2025 | -
Net Book Value
As at 30 November 2025 | 84
As at 1 December 2024 | 84

Subsidiaries
Details of the company's subsidiaries as at 30 November 2025 are as follows:

Name of undertaking | Registered Office | Class of shares held | Direct holding | Indirect holding
--- | --- | --- | --- | ---
Turing Biosystems SASU | France | Ordinary | 100.00% | -

6. Debtors

| 2025 |  | 2024
--- | --- | --- | ---
| £ |  | £
Due within one year
Other debtors | 3,720 |  | -
Corporation tax recoverable assets | 46,443 |  | 30,671
VAT | 2,638 |  | 12,628
Other taxes and social security | - |  | 20
Amounts owed by group undertakings | 70,197 |  | 70,277
| 122,998 |  | 113,596

7. Creditors: Amounts Falling Due Within One Year

| 2025 |  | 2024
--- | --- | --- | ---
| £ |  | £
Trade creditors | 970 |  | 28,227
Other taxes and social security | 4,593 |  | -
Net wages | 10 |  | -
Other creditors | 1,041 |  | 114
Accruals and deferred income | 4,025 |  | 2,150
Directors' loan accounts | 1,197 |  | 1,215
| 11,836 |  | 31,706

Page 5
Page 6
Turing Biosystems Ltd
Notes to the Financial Statements (continued)
For The Year Ended 30 November 2025
8. Share Capital

| 2025 |  | 2024
--- | --- | --- | ---
Allotted, called up and fully paid | £ |  | £
1,000,000 Ordinary Shares of £ 0.001 each | 1,000 |  | 1,000
468,766 Series Seed shares of £ 0.001 each | 469 |  | 469
| 1,469 |  | 1,469

Page 6